Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Pharmacology
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Molecular Pharmacology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit molpharm on Facebook
  • Follow molpharm on Twitter
  • Follow molpharm on LinkedIn
Research ArticleArticle

Demonstration of [3H]Cyclazocine Binding to Mutiple Opiate Receptor Sites

R. SUZANNE ZUKIN and STEPHEN R. ZUKIN
Molecular Pharmacology September 1981, 20 (2) 246-254;
R. SUZANNE ZUKIN
Department of Biochemistry, Albert Einstein College of Medicine, Bronx, New York 10461, and Department of Psychiatry, Mount Sinai School of Medicine, New York, New York 10029
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
STEPHEN R. ZUKIN
Department of Biochemistry, Albert Einstein College of Medicine, Bronx, New York 10461, and Department of Psychiatry, Mount Sinai School of Medicine, New York, New York 10029
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

Interaction of the psychotomimetic opiate cyclazocine with multiple receptor sites has been demonstrated biochemically. Cyclazocine has been postulated to interact with µ, κ, and σ opiate receptors (Martin et al., J. Pharmacol. Exp. Ther. 197:517-532 (1976).) In an effort to understand the molecular mechanisms involved in the neuropharmacological actions of this and closely related opiates we have studied the binding of [3H]cyclazocine to rat brain homogenates. Specific binding, defined as total binding minus binding in the presence of 10 µM nonradioactive cyclazocine, constitutes approximately 92% of total binding at 1.0 nM 3H-labeled ligand and 67% of total binding at 100 nM 3H-labeled ligand. Scatchard analyses utilizing various competing drugs reveal the apparent interaction of this drug with three distinct binding sites characterized by affinities of 0.2 nM, 11 nM, and 70 nM (50 nM Tris-HCl buffer, pH 7.4 at 4°). In contrast, many radiolabeled classical opiates and opioid peptides have been reported to exhibit biphasic binding but do not exhibit binding to a site of such low affinity. The high- and low-affinity [3H]cyclazocine sites exhibit differential sensitivities to sodium and also to the selective sulfhydryl reagent N-ethylmaleimide. In addition, all three sites exhibit greater than 50% loss of specific binding following incubation with trypsin (5 µg/ml) for 15 min at room temperature, and greater than 80% loss of specific binding following incubation at 60° for 15 min in the absence of added reagents. Together, these findings indicate that all three sites have a protein-like component. Competition analyses involving rank order determinations for a series of opiates and other drugs indicate that the cyclazocine binding sites represent, in order of decreasing affinity, the classical opiate receptor (the putative "µ" receptor), a second as yet uncharacterized opiate binding site, and the specific [3H]phencylidine binding site. Specific [3H]phencyclidine binding can be displaced by cyclazocine (IC50 = 350 nM) and by related benzomorphans, but not by classical opiates such as morphine or naloxone. We thus propose a common binding site in rat nervous tissue for phencyclidine and some of the benzomorphan opiates.

ACKNOWLEDGMENTS We thank Hoffmann-La Roche, Bristol Laboratories, and the National Institute on Drug Abuse for their respective gifts of levorphanol, ketamine, and phencyclidine analogues; Dr. Eric Simon for nalorphine and pentazocine; Dr. Arthur Jacobson for cyclazocine and phenazocine; Dr. Agu Pert for metazocine; Dr. Alan Gintzler for ethylketocyclazocine and ketocyclazocine; and Sterling-Winthrop, Inc., for cyclorphan, etazocine, and WIN derivatives. We also thank Ms. Gail D. Federoff and Ms. Melissa Fitz for excellent technical assistance, and Dr. Gavril Pasternak for technical advice and the use of his computer program for nonlinear regression analysis.

  • Copyright © 1981 by The American Society for Pharmacology and Experimental Therapeutics

MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Molecular Pharmacology
Vol. 20, Issue 2
1 Sep 1981
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Pharmacology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Demonstration of [3H]Cyclazocine Binding to Mutiple Opiate Receptor Sites
(Your Name) has forwarded a page to you from Molecular Pharmacology
(Your Name) thought you would be interested in this article in Molecular Pharmacology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

Demonstration of [3H]Cyclazocine Binding to Mutiple Opiate Receptor Sites

R. SUZANNE ZUKIN and STEPHEN R. ZUKIN
Molecular Pharmacology September 1, 1981, 20 (2) 246-254;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

Demonstration of [3H]Cyclazocine Binding to Mutiple Opiate Receptor Sites

R. SUZANNE ZUKIN and STEPHEN R. ZUKIN
Molecular Pharmacology September 1, 1981, 20 (2) 246-254;
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Therapeutic Effects of FGF23 Antagonists in Hyp Mice
  • TRPV3 and TRPV4 Channels Coassemble into Heterotetramers
  • Secretin Amino-Terminal Structure-Activity Relationships and Complementary Mutagenesis at the Site of Docking to the Secretin Receptor
Show more Article

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About Molecular Pharmacology
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Journal of Pharmacology and Experimental Therapeutics
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0111 (Online)

Copyright © 2022 by the American Society for Pharmacology and Experimental Therapeutics